Daxor Enters Agreement to Sell 765,958 Shares at $11.75 Each
Daxor Corporation entered into a definitive agreement with fundamental investors for the purchase and sale of an aggregate of 765,958 shares of its common stock at a purchase price per Share of $11.75. The offering is expected to close on or about January 26, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering to the Company are expected to be approximately $9M, before deducting placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for general corporate purposes, including working capital. Lake Street Capital Markets is acting as the exclusive placement agent for the offering.
Trade with 70% Backtested Accuracy
Analyst Views on DXR
About DXR
About the author
Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available
Daxor Corporation Milestone: Daxor Corporation celebrated the FDA 510(k) clearance of its next-generation, hand-held Blood Volume Analyzer (BVA) during a Nasdaq Closing Bell Ceremony on August 8, 2025.
Impact on Healthcare: The BVA technology aims to address the critical issue of accurately measuring blood volume, which can lead to improved patient outcomes and efficiencies in healthcare management, particularly for conditions like heart failure.
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories
Earnings Reports: Investors are receiving a variety of news on Thursday, particularly focused on earnings reports and other significant announcements in the stock market.
TipRanks Daily Wrap-Up: TipRanks provides a daily summary to help investors stay informed about the most important stock market headlines and developments.
Why Is Daxor Stock (DXR) Up 20% Today?
Daxor's FDA Clearance: Daxor's stock surged after receiving FDA clearance for its new Blood Volume Analyzer, which allows for accurate blood volume measurement and improved fluid management in patients with complex conditions.
Stock Performance and Analyst Rating: Following the news, Daxor's stock rose significantly, with heavy trading activity; however, Wall Street coverage remains limited, and an AI analyst rates the stock as Neutral due to mixed performance indicators.
Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System
Daxor Corporation's New Device: Daxor Corporation has received FDA clearance for its next-generation Blood Volume Analyzer (BVA), which allows for rapid, precise measurement of blood volume to improve fluid management in various clinical conditions, potentially reducing hospital stays and readmissions.
Impact on Healthcare: The BVA device aims to address the significant healthcare burden caused by inaccurate blood volume assessments, particularly in high-cost medical conditions like heart failure, by providing clinicians with objective data to make informed treatment decisions.
Daxor's Blood Volume Analysis Technology Accelerates Market Penetration with Three New Facility Adoptions
Expansion of Daxor's Technology: Daxor Corporation is expanding its blood volume analysis technology into three new hospitals, highlighting the growing acceptance of its BVA technology in improving patient care and reducing healthcare costs.
Positive Sales Outlook: The company anticipates accelerated sales growth throughout 2025 as more clinicians adopt its ezBVA Lab service and on-site analyzers for effective fluid management in cardiology and heart failure treatments.
Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal
Research Findings: A study from Duke University Medical Center published in the American Heart Journal demonstrates that Blood Volume Analysis (BVA) effectively differentiates between true anemia and dilutional pseudo-anemia in heart failure patients, which is crucial for appropriate treatment decisions.
Clinical Implications: The findings indicate that 60% of heart failure patients diagnosed with anemia have true anemia, while 40% have dilutional pseudo-anemia, highlighting the need for accurate blood volume measurement to improve patient outcomes and quality of life in heart failure management.
Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available
Daxor Corporation Milestone: Daxor Corporation celebrated the FDA 510(k) clearance of its next-generation, hand-held Blood Volume Analyzer (BVA) during a Nasdaq Closing Bell Ceremony on August 8, 2025.
Impact on Healthcare: The BVA technology aims to address the critical issue of accurately measuring blood volume, which can lead to improved patient outcomes and efficiencies in healthcare management, particularly for conditions like heart failure.
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories
Earnings Reports: Investors are receiving a variety of news on Thursday, particularly focused on earnings reports and other significant announcements in the stock market.
TipRanks Daily Wrap-Up: TipRanks provides a daily summary to help investors stay informed about the most important stock market headlines and developments.
Why Is Daxor Stock (DXR) Up 20% Today?
Daxor's FDA Clearance: Daxor's stock surged after receiving FDA clearance for its new Blood Volume Analyzer, which allows for accurate blood volume measurement and improved fluid management in patients with complex conditions.
Stock Performance and Analyst Rating: Following the news, Daxor's stock rose significantly, with heavy trading activity; however, Wall Street coverage remains limited, and an AI analyst rates the stock as Neutral due to mixed performance indicators.
Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System
Daxor Corporation's New Device: Daxor Corporation has received FDA clearance for its next-generation Blood Volume Analyzer (BVA), which allows for rapid, precise measurement of blood volume to improve fluid management in various clinical conditions, potentially reducing hospital stays and readmissions.
Impact on Healthcare: The BVA device aims to address the significant healthcare burden caused by inaccurate blood volume assessments, particularly in high-cost medical conditions like heart failure, by providing clinicians with objective data to make informed treatment decisions.
Daxor's Blood Volume Analysis Technology Accelerates Market Penetration with Three New Facility Adoptions
Expansion of Daxor's Technology: Daxor Corporation is expanding its blood volume analysis technology into three new hospitals, highlighting the growing acceptance of its BVA technology in improving patient care and reducing healthcare costs.
Positive Sales Outlook: The company anticipates accelerated sales growth throughout 2025 as more clinicians adopt its ezBVA Lab service and on-site analyzers for effective fluid management in cardiology and heart failure treatments.
Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal
Research Findings: A study from Duke University Medical Center published in the American Heart Journal demonstrates that Blood Volume Analysis (BVA) effectively differentiates between true anemia and dilutional pseudo-anemia in heart failure patients, which is crucial for appropriate treatment decisions.
Clinical Implications: The findings indicate that 60% of heart failure patients diagnosed with anemia have true anemia, while 40% have dilutional pseudo-anemia, highlighting the need for accurate blood volume measurement to improve patient outcomes and quality of life in heart failure management.
